Physician profile
Jacob Chacko
NPI 1346340551
$1,897.68
in general payments reported to CMS, 2019-2025
24 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $119 · 2021: $61.77 · 2022: $157 · 2023: $74.18 · 2024: $179 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $294.12 | 2019-2023 | |
| Glaxosmithkline, LLC. | $185.87 | 2019-2025 | Nucala |
| Insmed, INC. | $167.85 | 2019 | |
| Genzyme Corporation | $161.20 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $151.17 | 2022-2025 | Uptravi, Opsynvi |
| Sunovion Pharmaceuticals INC. | $150.57 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $99.70 | 2024-2025 | Dupixent |
| Grifols USA, LLC | $97.50 | 2019-2020 | |
| Electromed, INC. | $91.43 | 2019-2024 | Smartvest |
| Novartis Pharmaceuticals Corporation | $79.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.18 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $52.40 | 2019-2025 | Fasenra |
| Genentech USA, INC. | $47.96 | 2019 | |
| Csl Behring | $35.70 | 2024 | Haegarda |
| Verona Pharma, INC. | $31.83 | 2025 | Ohtuvayre |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $29.66 | 2023 | Hillrom - Life 2000 Ventilation System |
| Ani Pharmaceuticals, INC. | $27.54 | 2025 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $25.47 | 2019 | |
| Pfizer INC. | $23.18 | 2019 | |
| Recordati_rare_diseases_inc. | $20.76 | 2024 | Isturisa, Signifor Lar |
| Mylan Specialty L.P. | $13.73 | 2019 | |
| Medtronic, INC. | $13.25 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.87 | 2019 | |
| Pulmonx Corporation | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Chacko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.